Roximella 231

Diroximel fumarate

Cherry On Top

Making It Even Better

ZISTDARU

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study



A 5-week trial comparing the gastrointestinal tolerability of diroximel fumarate (DRF) and dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis. The study found that DRF-treated patients experienced **less severe gastrointestinal events** that lasted for **shorter durations** compared to those on DMF. Additionally, DRF demonstrated a **lower rate of treatment discontinuation** due to gastrointestinal adverse events.

Naismith RT, et al. CNS Drugs. 2020 Feb

Pharmacological Category:

- Fumaric acid derivatives, Nrf2 pathway activator

Dosage and Strength:

- Delayed-release Capsule, 231 mg

Indications:



Contraindications:

- Known hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients Roximella
- Co-administration with dimethyl fumarate

Adverse Effects:

- Flushing, abdominal pain, diarrhea, and nausea

Roximella has approximately 80% fewer GI-related side effects!

Dosing:

- Starting dose: 231 mg twice a day, for 7 days
- Maintenance dose after 7 days: 462 mg (administered as two 231 mg capsules) twice a day

Unit 404, Official 4th Floor, North Tower-Rosemall Complex, West Hemmat Highway, Tehran, Iran
www.zistdaru.com **info@zistdaru.com** **info@zistdaru.ir**
Postal Code: 1498711712 **Tel:** +982148241000